kras
2 stories tagged "kras"
Cancer
Twenty People, No Control Arm, and a Startup on the Side: Reading the Pancreatic Cancer Vaccine's Fine Print
Ninety percent of twenty volunteers made KRAS-specific T cells. None was shown to avoid cancer. Two of the investigators co-founded the company that licensed the shot from Johns Hopkins, which stands to collect royalties.
CancerPancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.
Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.